A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the NOVA Sirolimus Eluting Stent Versus the Apollo Stent

Sino Medical Sciences Technology Inc.1 site in 1 country272 target enrollmentApril 27, 2015

ConditionsIschemic Stroke

Overview

Phase: N/A
Intervention: Not specified
Conditions: Ischemic Stroke
Sponsor: Sino Medical Sciences Technology Inc.
Enrollment: 272
Locations: 1
Primary Endpoint: In stent restenosis rate (> 50% restenosis)
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Prospective, multi-center, randomized 1:1 single blind trial using NOVA sirolimus eluting stent versus Apollo bare metal stent conducted in approximately 15 interventional neurology centers in China. The study was sponsored by Sino Medical Sciences Technology Inc.

Detailed Description

The study will enroll 264 subjects overall in two groups (randomized 1:1). The study follow-up will occur at 1, 6 and 12 months post-stent implantation. All patients will undergo angiography assessment (DSA/CTA) at 12 months follow-up. Angiography assessment will be performed at baseline (pre- and post-procedure) and 12 months follow-up.

Registry

clinicaltrials.gov

Start Date

April 27, 2015

End Date

January 2020

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Sino Medical Sciences Technology Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•18 to 75 years of age;
•Primary or recurrent symptomatic intracranial arteriostenosis through the internal medicine treatment (i.e. stroke or transient ischemic attack within 90 days during the treatment with at least one anti-thrombotic drugs and vascular risk factor intervention e.g. hypertensors for hypertension and hypolipidemics for hyperlipidemia);
•No transient ischemic attack (TIA) or ischemic stroke occurred within 2 weeks prior to stenting procedure;
•≥70% stenosis of intracranial responsible vessel under the DSA angiography (as judged through the WASID method);
•Poor blood circulation in the side branch of responsible vessel area under the angiography within one week prior to stenting procedure:
•Score of blood circulation in the side branch under the DSA \<3 or blood flow rate peak ≥200cm/s at the systolic phase under the transcranial doppler ultrasonic examination (TCD); or no apparent side branch compensation in the responsible vessel area under CTA or score of blood circulation in the side branch under the CTA \<2;
•The target lesion reference diameter must be visually estimated to be ≥2.0 mm in diameter, and lesion length must be \<15 mm; no lesion observed in the distal vessel;
•Atherosclerosis lesions;
•Written informed consent.

Exclusion Criteria

•\>70% intracranial large-vessel stenosis beyond the responsible vessel;
•\>70% stenosis observed at the intracranial large-vessel distal to the responsible vessel or \>70% stenosis observed at the intracranial/extracranial large-vessel proximal to the responsible vessel;
•Acute ischemic stroke within 3 weeks;
•Obstruction of perforating branch artery under the skull MRI;
•Intracranial hemorrhage in the angiopathic area within 6 weeks;
•Patient was treated by thrombolytic therapy within 24 hours;
•Patients underwent surgery within 30 days or plan for surgery within 3 months post-stenting procedure;
•Severe calcified lesions;
•Patients have been treated by intracranial/extracranial stenting procedures prior to this study;
•Nonatherosclerosis lesions;

Outcomes

Primary Outcomes

In stent restenosis rate (> 50% restenosis)

Time Frame: 12 months post-procedure

Angiography assessment at 12 months post-procedure

Secondary Outcomes

Non-target vessels ischemic stroke event(between 30 days and 1 year post-procedure)
Target vessel ischemic stroke event(between 30 days and 1 year post-procedure)
Cerebral parenchyma hemorrhage, subarachnoid hemorrhage and intraventricular bleeding events(between 30 days and 1 year post-procedure)
Death event(between 30 days and 1 year post-procedure)
National Institutes of Health Stroke Scale (NIHSS) evaluation(at 1 and 12 months)
Stroke and death events(within 30 days after stenting)
Acute procedural success rate (stenosis < 30%)(1 year)
modulate RANK score （mRS）evaluation(at 1 and 12 months)
Montreal Cognitive Assessment (MoCA) evaluation(at 1 and 12 months)
Recurrent ischemic stroke in the involved vascular area(between 30 days and 1 year post-procedure)
Target vessel stroke or death events(within 30 days after stenting)
Transient ischemic attack event(within 1 year post-procedure)
EQ-5D score evaluation(at 12 months)